Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives Average Recommendation of “Hold” from Brokerages

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has received a consensus recommendation of “Hold” from the eight brokerages that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $6.75.

A number of analysts have recently issued reports on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inovio Pharmaceuticals in a report on Monday, December 29th. Piper Sandler reaffirmed an “overweight” rating and set a $6.00 price target (up previously from $5.00) on shares of Inovio Pharmaceuticals in a research note on Friday, November 14th. HC Wainwright reiterated a “neutral” rating on shares of Inovio Pharmaceuticals in a research report on Tuesday, December 30th. Citigroup restated a “market outperform” rating on shares of Inovio Pharmaceuticals in a research report on Tuesday, November 4th. Finally, UBS Group reiterated an “overweight” rating on shares of Inovio Pharmaceuticals in a research report on Friday, November 14th.

Inovio Pharmaceuticals News Roundup

Here are the key news stories impacting Inovio Pharmaceuticals this week:

• Negative Sentiment: Multiple plaintiff law firms are soliciting Inovio investors about a class action covering purchases between Oct. 10, 2023 and Dec. 26, 2025 and warning of an April 7, 2026 lead‑plaintiff deadline. These notices increase the likelihood of consolidated litigation and potential legal exposure. Rosen Law Firm notice
• Negative Sentiment: The Gross Law Firm announced the filing of a securities class action on behalf of Inovio shareholders, increasing the number of firms pursuing claims and the public attention on alleged company misstatements. Gross Law Firm article
• Negative Sentiment: Law Offices of Frank R. Cruz is soliciting inquiries from INO shareholders about securities fraud claims—another firm publicizing potential litigation and recruiting lead plaintiffs. Frank R. Cruz notice
• Negative Sentiment: Levi & Korsinsky issued a class action notice with the same class period and April 7, 2026 deadline, emphasizing potential recoveries for affected shareholders. Levi & Korsinsky release
• Negative Sentiment: Pomerantz filed a class action naming Inovio and certain officers in the Eastern District of Pennsylvania (docket 26-cv-00803), representing a formal lawsuit rather than only a notice. This is a direct adverse legal development. Pomerantz filing
• Negative Sentiment: The Schall Law Firm reminded investors of the suit and the April 7 deadline, signaling competition among firms to lead the litigation which can affect recovery dynamics and publicity. Schall Law Firm notice
• Negative Sentiment: Glancy Prongay Wolke & Rotter and additional firms have also published notices of the filed securities fraud action, underscoring broad legal attention that could lead to defense costs, settlements or judgment risk. Glancy notice
• Negative Sentiment: Additional Rosen and PR Newswire notices reiterate the class period and April 7 deadline, increasing investor awareness and the chance of more filings or consolidation motions. Rosen/PR Newswire release

Inovio Pharmaceuticals Price Performance

Shares of INO opened at $1.67 on Thursday. Inovio Pharmaceuticals has a 1-year low of $1.30 and a 1-year high of $2.98. The company has a market capitalization of $111.44 million, a P/E ratio of -0.64 and a beta of 1.72. The firm’s 50 day simple moving average is $1.77 and its 200 day simple moving average is $2.05.

Hedge Funds Weigh In On Inovio Pharmaceuticals

A number of large investors have recently bought and sold shares of the stock. Janus Henderson Group PLC boosted its stake in shares of Inovio Pharmaceuticals by 1.3% during the fourth quarter. Janus Henderson Group PLC now owns 3,308,406 shares of the biopharmaceutical company’s stock valued at $5,773,000 after purchasing an additional 42,146 shares during the period. Bridgeway Capital Management LLC bought a new stake in Inovio Pharmaceuticals during the 4th quarter valued at $301,000. 683 Capital Management LLC bought a new stake in Inovio Pharmaceuticals during the 4th quarter valued at $433,000. OMERS ADMINISTRATION Corp purchased a new stake in Inovio Pharmaceuticals during the 4th quarter valued at $388,000. Finally, Marshall Wace LLP bought a new stake in Inovio Pharmaceuticals in the 4th quarter worth $143,000. 26.79% of the stock is owned by hedge funds and other institutional investors.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.